Co-Diagnostics
CODX
83 hedge funds and large institutions have $71.9M invested in Co-Diagnostics in 2020 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 28 increasing their positions, 22 reducing their positions, and 12 closing their positions.
27% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 22
25% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 12
15% more call options, than puts
Call options by funds: $10.3M | Put options by funds: $8.95M
2% more funds holding
Funds holding: 81 → 83 (+2)
0% more ownership
Funds ownership: 0.91% → 0.91% (+0%)
30% less capital invested
Capital invested by funds: $103M → $71.9M (-$31.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.86M |
| 2 |
Principal Financial Group
Des Moines,
Iowa
|
+$1.85M |
| 3 |
Bank Julius Baer & Co
Zurich,
Switzerland
|
+$1.82M |
| 4 |
BlackRock
New York
|
+$1.48M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
+$788K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$3.32M |
| 2 |
Morgan Stanley
New York
|
-$1.41M |
| 3 |
Wells Fargo
San Francisco,
California
|
-$1.2M |
| 4 |
JP Morgan Chase
New York
|
-$907K |
| 5 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$809K |
CODX Hedge Fund Activity: Q4 2020 in Review
83 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Co-Diagnostics (CODX) for Q4 2020, worth a combined $71.9M — down 30% from $103M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new CODX positions and 12 closed out — a net gain of 3 holders — while 28 added to existing stakes and 22 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.86M. The largest seller was Susquehanna International Group, cutting an estimated $3.32M.
- 83 institutional investors held Co-Diagnostics (CODX) as of Q4 2020, up from 81 in Q3 2020.
- Funds reported $71.9M of Co-Diagnostics stock for Q4 2020, down 30% quarter-over-quarter.
- 15 funds opened new Co-Diagnostics positions in Q4 2020 and 12 closed out, a net change of +3 holders.
- The largest Co-Diagnostics buyer in Q4 2020 was Vanguard Group, an estimated $1.86M added.
- The largest Co-Diagnostics seller in Q4 2020 was Susquehanna International Group, an estimated $3.32M sold.
Based on aggregated 13F filings for Q4 2020.